Exelixis EXEL
NASDAQ EXEL
$58.41 -0.24 (-0.41%)
At close: Sep 30, 2026 · 4:00 PM EDT

Exelixis (EXEL) Capital Leases (2017 - 2018)

Updated

Exelixis (EXEL) reported Capital Leases of $20.65 million for Q2 2018.

Analysis

Exelixis (EXEL) Capital Leases (2017 - 2018) Analysis & Trends

At the end of FY2017, Exelixis posted Capital Leases of $14.53 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 Exelixis 14.54 Bn 10.87 Bn 608.03 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 29, 2018 20.65 Mn
Dec 29, 2017 14.53 Mn
API Access

Exelixis Capital Leases API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=capital-leases&ticker=EXEL&period=max&api_key=YOUR_API_KEY